PrimeRFP SCOUT · Federal Contract Recompete Brief

HHSN26100019Research development production and support — Leidos Biomedical Research, Inc

Leidos Biomedical Research, Inc holds $2.1B across 186 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent HHSN261201500003I. PoP ended Sep 18, 2021 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Nih Nci

Awarding office

Leidos Biomedical Research, Inc

Recipient

Sep 18, 2021

PoP end

$0

Obligated

$27.5M

Potential

561210

NAICS

M1HA

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Leidos Biomedical Research, Inc — $90

Contract facts

Federal

Contract numberHHSN26100019

Also listed asHHSN261201500003I-HHSN26100019

AgencyNih Nci

Awarding officeNih Nci

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentLeidos Biomedical Research, Inc

CAGE3LYK6

UEIHV8BH9BPG8Y9

NAICS561210

No full NAICS 561210 intel page yet. Browse NAICS intelligence

PSCM1HA

Parent IDIQ / IDVHHSN261201500003I

Place of performanceFREDERICK MD

Pricing typeCost No Fee

Extent competedNot Competed

Related solicitationN01CO5240180

PoP startSep 19, 2016

PoP end (current)Sep 18, 2021

Obligated$0

Current value$27.5M

Potential value$27.5M

RESEARCH, DEVELOPMENT, PRODUCTION AND SUPPORT FOR CLINICAL TRIALS BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES (BNMABS) is a federal award for Nih Nci held by Leidos Biomedical Research, Inc. Estimated value $27.5M ($0 obligated). Current period of performance ends Sep 18, 2021. Place of performance: FREDERICK MD. Related solicitation N01CO5240180.

RESEARCH, DEVELOPMENT, PRODUCTION AND SUPPORT FOR CLINICAL TRIALS BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES (BNMABS)

Recompete timing

Public

● Past PoP end (1815 days ago)

Current PoP ended Sep 18, 2021 (1815 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Leidos Biomedical Research, Inc — $2.1B obligated across 186 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$2.1B · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

75N91021F00017

ELABORATION AND USE OF SYNGENIC PRE-CLINICAL MODELS FOR CANCER DRUG DEVELOPMENT

$12.1M

Sep 15, 2026

75N91021F00016

DEVELOPMENT OF CANINE IMMUNOTHERAPY TARGETED AGENTS

$6.6M

Sep 15, 2026

75N91021F00018

INFRASTRUCTURE IMPROVEMENTS

$4.6M

Sep 24, 2026

HHSN26100039

RETROSPECTIVE TUMOR CHARACTERIZATION ANALYSIS (MOONSHOT)

$21.3M

Sep 30, 2026

75N91018F00080

HHSN261201500003I; HHSN26100080; 400.001.0080.0001; NCI OD-FREDERICK; APPROPRIATED; 125073…

$10.0M

Oct 2, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract HHSN26100019?

HHSN26100019 (Research development production and support) is a Nih Nci award with a potential value of $27.5M, currently held by Leidos Biomedical Research, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded HHSN26100019?

Nih Nci awarded HHSN26100019 to Leidos Biomedical Research, Inc (potential $27.5M).

Who is the incumbent on HHSN26100019?

Leidos Biomedical Research, Inc is the incumbent with $2.1B across 186 related awards in SCOUT’s public footprint. The current period of performance ends Sep 18, 2021.

When does Leidos Biomedical Research, Inc’s HHSN26100019 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 18, 2021. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on HHSN26100019 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Dec 20, 2021